Siemers Eric 4

What Happened

• Eric Siemers, Chief Medical Officer of Acumen Pharmaceuticals (ABOS), received equity awards on 2026-01-16: 99,133 restricted stock units (RSUs) and 148,700 derivative/option-related shares. Both grants were issued at $0.00 (no cash paid) as reported on a Form 4 filed 2026-01-21. These are grants/awards, not open-market purchases or sales.

Key Details

• Transaction date: 2026-01-16; Form 4 filed: 2026-01-21 (filed on the second business day after the grant; appears timely).
• Grant values reported at $0.00 per share (typical for RSU/option grants); total cash outlay = $0 at grant.
• Vesting: the 99,133 RSUs vest in three equal annual installments starting one year after the grant date (Footnote F1). The 148,700 derivative/option shares vest in 48 equal monthly installments over four years (Footnote F2).
• Shares owned following the reported transactions: not specified in the filing.
• Transaction code: A = Award/Grant. No sale, purchase (P/S), or tax-withholding (F) entry reported in this filing.

Context

• RSUs represent a contingent right to receive shares upon vesting; they do not provide immediate stock ownership until each tranche vests. The derivative/option-style award will vest monthly, meaning shares become exercisable/owned over time if the reporting person remains in service.
• Awards are common compensation tools for executives and do not, by themselves, indicate a buy or sell signal; they reflect company compensation decisions rather than an insider trading preference.